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Abstract
Objective—Inflammatory mediators, such as PGE2 and IL-1β, are produced by osteoarthritic 
joint tissues, where they may contribute to disease pathogenesis. We examined whether 
inflammation, reflected in plasma and peripheral blood leukocytes (PBLs) reflected presence of 
osteoarthritis (OA), progression or symptoms in patients with symptomatic knee osteoarthritis 
(SKOA).
Methods—SKOA patients were enrolled in a 24-month prospective study of radiographic 
progression. Standardized knee radiographs were obtained at baseline and 24 months. Biomarkers 
assessed at baseline included plasma lipids PGE2 and 15-HETE, and transcriptome analysis of 
PBLs by microarray and qPCR.
Results—Baseline PGE synthases (PGES) by PBL microarray gene expression, and plasma 
PGE2 distinguished SKOA patients from non-OA controls (AUCs 0.87 and 0.89 respectively, 
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p<0.0001). Baseline plasma 15-HETE was significantly elevated in SKOA versus non-OA 
controls (p<0.019). In the 146 patients who completed the 24-month study, elevated baseline 
expression of IL-1β, TNFα and COX-2 mRNA in PBLs predicted higher risk for radiographic 
progression by joint space narrowing (JSN). In a multivariate model, AUC point estimates of 
models containing COX-2 in combination with demographic traits overlap the confidence interval 
of the base model in two out of the three JSN outcome measures (JSN >0.0mm, >0.2mm and 
>0.5mm, AUC=0.62–0.67).
Conclusion—Inflammatory plasma lipid biomarkers PGE2 and 15-HETE identify patients with 
SKOA. PBL inflammatory transcriptome identifies a subset of SKOA patients at higher risk for 
radiographic progression. These findings may reflect low-grade inflammation in OA and may be 
useful as diagnostic and prognostic biomarkers in clinical development of disease-modifying OA 
drugs.
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INTRODUCTION
Osteoarthritis (OA), a disease of the whole joint that affects cartilage, synovium, 
subchondral bone, menisci, muscle and ligaments, is the most common type of arthritis (1). 
A recent report from the Centers for Disease Control estimates that 52.5 million US adults 
had arthritis in 2010–2012, an increase from 2007–2009 (50 million); given its prevalence, 
OA likely accounts for at least half of this total. In addition, 22.7 million subjects (43.2% of 
adults with arthritis) reported activity limitations because of arthritis (2). While formerly 
considered a non-inflammatory joint disease, it now is well-appreciated that inflammatory 
mediators are produced by articular tissues in OA and have been implicated in its 
pathogenesis (3–5). Inflammatory cascades in OA joint tissues are driven by a variety of 
enzymes, prominently cyclooxygenase (COX), which catalyzes formation of prostaglandins 
from arachidonic acid. COX consists of at least two isoforms, constitutive (COX-1) and 
inducible (COX-2). In addition, two prostaglandin E2 (PGE2) synthases (constitutive PGES 
and inducible-membrane PGES) convert prostaglandin H2 (PGH2) into PGE2. We and 
others have shown that cartilage, synovium and infrapatellar fat pads from OA patients 
produce elevated levels of PGE2 and other inflammatory mediators in ex vivo cultures (5,6). 
Indeed, cytokines, nerve growth factor, chemokines and prostaglandins produced by joint 
tissues promote pain and cartilage degeneration, while synovitis has been associated with 
cartilage loss in patients with knee OA (7,8).
Currently, the US Food and Drug Administration considers slowing of joint space narrowing 
(JSN) as an outcome for trials of disease-modifying OA drugs (DMOADs), but to date no 
drugs are approved for this indication in the US or Europe. Radiographic changes occur well 
after histological and biochemical changes in joint tissues (9). Thus, future development of 
DMOADs would be facilitated by validated prognostic biomarkers that identify subsets of 
patients at risk for progressive disease. Additionally, early diagnosis of OA, ideally at a time 
that allows effective intervention and before radiographic damage has occurred, will require 
improved diagnostic imaging and biochemical markers.
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We have previously reported, in a prospective study of patients with SKOA, that 
transcriptome profiling of circulating PBL could identify patients at risk for disease 
progression (4). In the current study, we expand those findings to show in three different 
populations that transcriptome analysis of PBLs identifies a subset of SKOA patients with 
elevation of IL-1β, TNFα and/or COX-2 who are at increased risk for radiographic 
progression at 24 months. Moreover, in a multivariate model, age/gender/body mass index 
(BMI) only did not predict progression, whereas addition of PBL expression data of two 
genes improved prediction of progression. Finally, our data show that plasma levels of 
PGE2 and 15-hydroxyeicosatetraenoic acid (15-HETE) are elevated in SKOA patients 
relative to non-OA controls. Thus, low-grade chronic inflammation in OA joint tissues is 
reflected systemically and can have both diagnostic and prognostic value.
PATIENTS AND METHODS
Three independent cohorts of SKOA patients were studied
NYUHJD Learning Cohort—Forty-four individuals with SKOA and 25 non-OA control 
subjects were enrolled in a cross-sectional study. Knee OA was diagnosed by referring 
physicians according to 1986 American College of Rheumatology (ACR) classification 
criteria (10), and patients met clinical and either radiographic (11) or laboratory criteria for 
diagnosis of idiopathic knee OA. This cohort was used as a discovery cohort for microarray 
gene expression studies. The preliminary observation of the association of OA with PBL 
inflammatory gene expression was published, as were patient characteristics and detailed 
inclusion/exclusion criteria (4).
NYUHJD Progression Cohort—As part of an NIH-funded study, an independent cohort 
of 181 patients with SKOA was assessed at baseline and enrolled in a 24-month prospective 
study. These individuals met ACR clinical symptomatic criteria (10,11). All patients 
underwent bilateral standardized weight-bearing fixed-flexion posteroanterior (PA) knee 
radiographs using the SynaFlexer™ X-ray positioning frame (Synarc). We also screened 41 
age-matched healthy controls and enrolled 21 subjects who had KL score <1 and no pain in 
either knee. All patients were examined by one of two NYUHJD investigators (SK,JS) every 
6 months during this study; 146 patients completed the 24-month observation period. 
Radiographic assessments at baseline and 24 months included bilateral (signal and non-
signal knee) KL grade and medial joint space width (JSW), measured at the mid-portion of 
the joint space via electronic calipers by two musculoskeletal radiologists blinded to patient 
information. Disagreements between the two readers were resolved by consensus. Cohen’s 
kappa coefficients for inter-rater agreement for KL scores of right and left knees were 0.85 
and 0.77, respectively, and >0.85 for most other radiographic outcome measures. 
Concordance correlation coefficients were >0.90 for JSW measurements. We collected 
heparinized plasma and RNA from PBLs from each subject (SKOA and non-OA) at 
baseline.
Pfizer Cohort—The Pfizer Cohort included 78 Caucasian subjects, 66 with OA and 12 
non-OA controls. Mean(SD) age in the OA group was 61.2(8.7) years; 64% were female. In 
the non-OA control group, mean(SD) age was 58.8(2.9) years; 66% were female. The OA 
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cases were derived from three Pfizer-sponsored studies in the US and UK, with 
radiologically confirmed painful knee OA. The non-OA control cohort (recruited from a 
single Canadian site) included subjects who were 55 years old or older, with no clinical 
signs or symptoms of OA. NSAID treatment in OA patients and controls was discontinued 
one week prior to plasma PGE2 determination. The study design has been described 
elsewhere in detail (12).
Laboratory Methods
Sample collection—Blood samples from NYUHJD cohorts were collected in serum 
collection tubes for serum and heparinized pyrogen-free tubes (BD Biosciences) for 
isolation of PBLs [as described previously (4)]. Blood was processed within 30–60 min of 
collection. Plasma samples were aliquoted and stored at −70°C until tested.
Whole blood incubation system—To determine whether PBLs from SKOA patients, 
which exhibit up-regulation of mPGES, were “primed” to produce PGE2, we measured 
production of PGE2 by whole blood cultured (24 h) ex vivo without any stimulus. Briefly, 1-
milliliter blood samples were collected in heparinized pyrogen-free glass tubes, diluted 1:1 
with PBS, and incubated for 24h in CO2 incubator as described (13). Samples were 
centrifuged at 3,500 rpm at 4°C, and clear plasma stored at −70°C until tested.
PGE2 measurements—Plasma samples from the two NYUHJD cohorts (Learning and 
Progression) were analyzed for PGE2 by the ACE EIA kit (Cayman Chemical Company). 
For the Pfizer cohort as well as subset of NYUHJD progression cohort and non-OA controls, 
plasma PGE2 and 15-HETE levels were measured using a two-dimensional liquid 
chromatography tandem mass spectrometry (LC-MS/MS) (Agilent Technologies) interfaced 
to API 4000 Qtrap mass spectrometer (MDS-Sciex) operated in the multiple-reaction 
monitoring mode. Plasma proteins were precipitated with 70% acetonitrile in the presence of 
deuterium-labeled PGE2 and 15-HETE internal standards; supernatants were analyzed for 
levels of PGE2 and 15-HETE. Selected analytes were specifically detected by monitoring 
retention times and ion pairs corresponding to parent and specific fragment ion mass-to-
charge ratios.
Urinary type II collagen neoepitope (uTIINE) peptide measurements—For the 
Pfizer cohort, urinary levels of type II collagen neoepitope peptides were measured by LC-
MS/MS assay in positive ion mode using multiple reactions monitoring on triple quadrupole 
mass spectrometer (14,15). Briefly, the assay measures urinary levels of a specific 45-
amino-acid-long peptide with 5 hydroxylations on proline residues, a neoepitope peptide 
that has been shown, both in vitro and ex vivo, to be produced by MMPs.
Total RNA isolation—Total RNA was purified from PBLs by the QIAGEN RNeasy kit, 
aliquoted and stored at –70°C (4). Quality of RNA was assessed by reading of optical 
density at 260 and 280 nm.
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Real Time PCR (qPCR)—Total RNA (1 μg) was primed with oligo(dT) 18 primers and 
cDNA synthesized using the cDNA synthesis kit (Clontech). Predesigned TaqMan primer 
sets (Applied Biosystems) were used and PCR reactions performed as described (4).
Labeling and hybridization of microarray—Five micrograms of total RNA were used 
for first-strand synthesis using a T7-(dT)24 oligomer. Complementary RNA was synthesized 
(Affymetrix) and purified using the QIAGEN RNeasy kit, fragmented at 95ºC for 35 min for 
target preparation, and hybridized on HG-U133A-1.0 human microarray (Affymetrix).
Normalization of microarray data—Microarray data were normalized using the Robust 
Multi-array Average (RMA) method (16,17).
Statistical Methods—We assessed associations and discrimination/predictive power of 
single biomarkers with outcomes of interest (OA incidence, KL severity, JSN) using the 
following statistical tools:
i. Analysis of partial correlations (adjusted for age, gender and BMI) of biomarkers 
with continuous outcome variables (e.g., JSN).
ii. Assessing predictivity of biomarkers for dichotomized outcome variables (e.g., KL 
1/2 vs. KL 3/4) with the area under receiver operating characteristic curve (AUC) 
and logistic regression (either unadjusted or adjusted for age, gender and BMI). 
The AUC (also known as c-statistic) (18) is independent of the prevalence of the 
positive class and therefore well-suited to case-control designs. To derive 
confidence intervals around AUC estimates and assess statistical significance under 
the null hypothesis (i.e., no predictive signal), we used DeLong’s non-parametric 
test (19).
iii. Comparing the means of a continuous outcome variable (e.g., JSN) for groups of 
patients defined based on biomarker values using Student’s two-tailed t-test.
Statistical significance was assessed at 5% alpha level with correction for multiple 
comparisons using the approach of Benjamini and Hochberg (20).
For the JSN outcome variable, we defined non-progressors as having JSN≤0.0mm/24 
months, and three subgroups of progressors with JSN >0.0, >0.2, and >0.5mm/24 months. 
We selected these JSN thresholds based on Emrani et al (21) and recommendations of The 
European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis 
(ESCEO) (22).
For building predictive multivariate models of a dichotomized outcome variable based on 
multiple biomarkers, we used support vector machines (23). The null model against which 
all other predictive models are compared and p-values are calculated is the random model 
(i.e., coin-flipping model). The random model has AUC of 0.5. For estimating future 
predictivity of multivariate predictive models, we used 10-fold stratified cross-validation 
repeated with 100 different splits of data into 10-folds (24,25). We used this model to further 
investigate the prognostic value of plasma biomarker PGE2 and PBL gene expression, with 
Attur et al. Page 5













age, gender and BMI for predicting JSN. We did not use 15-HETE in this analysis because 
data were only available for 43 subjects.
We developed the following models for each predictive task based on:
1. only age, gender and BMI;
2. age/gender/BMI and PBL COX-2 gene expression;
3. age/gender/BMI and PBL IL-1β gene expression;
4. age/gender/BMI and PBL TNFα gene expression;
5. age/gender/BMI and 2 PBL (COX-2 and IL-1β);
6. age/gender/BMI and 2 PBL (COX-2 and TNFα);
7. age/gender/BMI and 2 PBL (IL-1β and TNFα);
8. age/gender/BMI and 3 PBL (COX-2, IL-1β, TNFα);
9. age/gender/BMI, 3 PBL (COX-2, IL-1β, TNFα), and plasma PGE2.
This multivariate method can fit both simple and complex functions, avoids overfitting by 
using effective regularization strategies, and has shown excellent empirical performance in a 
wide range of biomedical predictive modeling applications (26,27). This protocol provides 
unbiased estimates of predictivity, and has low variance as a result of using 100 different 
splits into 10-folds (25). We used Matlab libSVM (http://www.csie.ntu.edu.tw/~cjlin/
libsvm/) implementation of SVMs, and R implementation of GLM. All other codes were 
custom-written and executed in Matlab.
RESULTS
NYUHJD Learning Cohort
Approximately 25% of participants were male, and 72% were non-Hispanic. Mean(SD) age 
of patients in the OA group was 65.7(10.7) years, 70% were female, and mean(SD) BMI 
was 27.4(4.0) kg/m2. In the non-OA control group, mean(SD) age was 54.6(9.5), 73% were 
female, and mean(SD) BMI was 24.9(3.9) kg/m2 (Supplemental Table 1).
NYUHJD SKOA Progression Cohort
Baseline demographic and clinical characteristics, and differences in these parameters 
between SKOA and control subjects, are shown in Supplemental Table 1. Mean(SD) age of 
patients in the OA group was 62.5(10.5) years, 64.5% were female, and mean(SD) BMI was 
26.7(3.5) kg/m2. Mean total WOMAC (range 1–300) and VAS pain (range 1–100) scores 
were 114.6(67.8) and 43.6(28.6), respectively. In the control group, mean age was 56.2(8.8), 
43% were female and mean BMI was 27.1(3.1) kg/m2.
Plasma PGE2 and 15-HETE levels are elevated in SKOA in three independent cohorts
We determined baseline plasma PGE2 levels in SKOA and control subjects from the 
NYUHJD Learning and Progression cohorts. As shown in Figure 1A-B, SKOA patients 
from both cohorts had significantly higher PGE2 levels [1.45-fold (p=0.0038) and 1.65-fold 
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(p<0.0001), respectively] than non-OA controls. Not surprisingly, among SKOA patients in 
the Progression cohort, plasma PGE2 levels were lower in NSAID users (128.94 vs.160.67 
pg/ml; p=0.044) than non-users. Elevations of plasma PGE2 (p<0.001) were also found in 
the separate Pfizer cohort of SKOA patients (Figure 1C) and distinguished SKOA cases 
from non-OA controls with 0.99 AUC (95% CI: 0.89–1.00; p<0.0001). Figure 1D also 
illustrates that plasma elevations of PGE2, along with age, gender and BMI, distinguished 
NYUHJD progression cohort SKOA cases from non-OA controls with 0.89 AUC (95% CI: 
0.83–0.97; p<0.0001).
As shown in Figure 2A–B, another lipid molecule, 15-HETE, was significantly higher 
(p=0.0195 and p<0.0001) in plasma of SKOA cases than non-OA controls in both NYUHJD 
Progression and Pfizer cohorts. In the Pfizer cohort, as expected, urinary type II collagen 
neoepitope (uTIINE), measured as a positive control, was increased in SKOA (p<0.0001) 
(Figure 2C). Both 15-HETE and uTIINE distinguished Pfizer SKOA cases from non-OA 
controls, with 0.95 AUC (95% CI: 0.89–1.00; p<0.0001) and 0.85 AUC (95% CI: 0.72–
0.98; p<0.0001), respectively. Significantly elevated PGE2 and 15-HETE (p=0.0097 and 
p=0.0195, respectively) in NYUHJD Progression SKOA cases versus non-OA controls were 
also confirmed by LC-MS/MS (data not shown).
Elevated expression of prostaglandin E synthase (PGES) mRNA in PBLs from SKOA 
patients
Our previous studies using an Affymetrix array gene expression platform showed that 
COX-2 was differentially expressed in PBLs from a subset of OA patients in our NYUHJD 
learning cohort (4). We next explored, in the NYU learning cohort, microarray data for 
expression of PGES terminal enzymes in PGE2 synthesis. We examined membrane and 
cytosolic PGES (mPGES and cPGES, respectively) for expression and predictive utility to 
differentiate SKOA cases from non-OA controls using a multivariate predictive modeling 
methodology. As shown in Figure 3A, unsupervised hierarchical clustering of probe sets 
representing mPGES (probe set 207388_s_at, 210367_s_at, 218083_at) and cPGES 
(200627_at) distinguished SKOA cases from non-OA controls. The same probe sets 
distinguished NYUHJD learning cohort SKOA cases from controls along with age/
gender/BMI with 0.87 AUC (95% CI: 0.78–0.95, p<0.0001) as estimated by 10-fold cross-
validation protocol repeated 100 times (25). Among these four probe sets, the mPGES 
isoform 1 probe set 207388_s_at alone and with age/gender/BMI distinguished SKOA cases 
from non-OA controls with 0.82 AUC (95% CI: 0.71–0.94; p<0.0001) and 0.86 AUC (95% 
CI: 0.77–0.94; p<0.0001), respectively (Figure 3B).
Elevated expression of PGES is associated with increased PGE2 production in vitro. At 24h, 
PGE2 levels (121.7±46.73 pg/ml) did not change significantly in controls, but increased 3.5-
fold over baseline in SKOA patients (430.2±211.4), indicating that the elevated expression 
of COX-2/mPGES mRNA was reflected in increased lipid product (PGE2) generation 
(p<0.0001). Similar to baseline plasma PGE2 levels (Figure 1A-B), PGE2 levels produced 
by PBLs following ex vivo culture (24h) also significantly distinguished SKOA patients 
from non-OA controls with 0.96 AUC (95% CI: 0.89–1.0; p<0.0001; Figure 3C).
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Joint space narrowing (JSN) in NYUHJD SKOA completers
In our completer cohort (n=146), the mean JSN was 0.32 mm over 24 months. This rate of 
progression for the entire cohort of 0.16 mm/year is consistent with findings reviewed by 
Emrani et al (21). Out of 146 completers, 18 patients with predominantly lateral 
compartment disease and 17 with JSW 0mm at baseline were excluded. Lateral 
compartment OA differs from medial compartment OA with respect to risk factors for 
disease severity and progression (28). Therefore, in order to reduce heterogeneity of the 
SKOA population, we performed analyses restricted to patients with medial compartment 
disease (n=111). Of this subgroup of completers, 35% showed no JSN and were designated 
as “non-progressors”; 58% exhibited JSN ≥0.2mm/24 months; 40% exhibited JSN ≥0.5 
mm/24 months, and were designated as “fast progressors.”
PBL IL-1β, TNFα and COX2 expression define SKOA patient subgroups with radiographic 
progression
We previously reported, in a smaller number of SKOA subjects (n=78), that increased PBL 
expression of IL-1β was associated with increased JSN at 24 months (4). These 78 subjects 
from the previous study are a subgroup of NYUHJD progression cohort (n=146 completers), 
and include the 18 subjects with lateral compartment OA disease excluded from certain 
analyses, as noted above. In the expanded NYUHJD progression cohort we performed our 
analysis with all 146 SKOA patients (gene expression data were available for 144) who had 
completed 24-month trials, and defined radiographic progression as change in radiographic 
JSW (JSN) over 24 months. As shown in Supplemental Table 2, we dichotomized SKOA 
patients based on median expression levels of IL-1β, TNFα and COX-2 determined by 
qPCR. Patients who expressed these inflammatory genes above median levels, labeled as 
OAIL-1β, OATNFα and OACOX-2, had more rapid radiographic progression (mean JSN >0.5 
mm/24 months) than patients with median levels or lower.
We also examined SKOA patients with predominant medial compartment disease. As shown 
in Table 1, these SKOA patients with PBL inflammatory phenotype (OAIL-1, OATNFα or 
OACOX-2) had more rapid radiographic progression than patients whose PBL inflammatory 
gene expression was below the median. Statistical significance was achieved for all three 
genes. Furthermore, increased levels of IL-1β, TNFα, and COX-2 identified “fast 
progressors” (mean JSN 0=0.71, 0.75 and 0.71 mm/24 months, respectively, for each 
group), as opposed to “slow progressors” (mean JSN range 0.29–0.34 mm/24 months) 
(Table 1, Supplemental Table 2). Additionally, in a cross-sectional analysis of 178 patients 
studied at baseline, patients with elevated IL-1β mRNA levels (>2-fold) had significantly 
higher WOMAC and VAS pain scores (Supplemental Table 3).
Association of single biomarker(s) with JSN
We performed Fisher’s partial correlation analyses of biomarkers with JSN, adjusted for 
age, gender and BMI. Among lipid markers, 15-HETE was significantly correlated with JSN 
(r=0.374; p=0.022); among PBL transcriptome markers, PBL COX-2 levels were 
significantly correlated (r=0.214; p=0.029) (Supplemental Table 4).
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As shown in Table 2, PBL COX-2 levels significantly predicted SKOA in all three 
progression groups with AUC=0.68–0.71 (p=0.001). However, PBL IL-1β significantly 
predicted only fast progressors (AUC=0.67; p=0.015) and approached significance in slow 
progressors. PBL TNFα and plasma PGE2 and 15-HETE did not significantly predict 
progressors in this analysis. Only PBL COX-2 expression significantly distinguished all 
groups of progressors from non-progressors independently of age, gender, BMI and KL 
score (Table 2), by both ROC and LR analysis. PBL IL-1β approached statistical 
significance in predicting fast progressors after adjustment for age, gender, and BMI (Table 
2).
Association of multiple markers with JSN
In these models, demographic traits and clinical characteristics alone did not predict 
progression. It is important to note that AUC point estimates of models containing COX-2 in 
combination with demographic traits and clinical characteristics overlap the confidence 
interval of the base model in 2 out of the 3 JSN outcome measures (Table 3) as estimated by 
10-fold cross-validation protocol repeated 100 times (25).
DISCUSSION
In the present study, we examined patients with SKOA for evidence of inflammation as 
reflected by plasma levels of inflammatory mediators PGE2 and 15-HETE, and PBL 
expression of COX-2 and inflammatory cytokines IL-1β and TNFα. Elevated levels of 
PGE2 and 15-HETE were associated with incidence of SKOA, and PBL expression of the 
cytokines was associated with radiographic JSN over 24 months. Furthermore, we validated 
previous findings that patients with elevated PBL expression of IL-1β (OAIL-1 subclass) 
exhibit increased risk of radiographic progression (4). Based on the recently proposed 
BIPED system for classification of biomarkers in OA (29), we identified candidate 
diagnostic and prognostic biomarkers of OA.
The diagnostic plasma biomarkers that statistically differentiate OA patients from controls 
are the lipid mediators PGE2 and 15-HETE. Plasma PGE2 levels were 2-fold higher in 
SKOA patients versus non-OA controls in both NYUHJD (AUC 0.89; p<0.0001) and Pfizer 
cohorts (AUC 0.99; p<0.0001). Thus, eicosanoids of both the cyclooxygenase and 
lipoxygenase pathways are produced in sufficient quantities by joint tissues to be reflected in 
plasma in patients with SKOA. PGE2 plays a role in cartilage degeneration and/or synovial 
tissue inflammation in OA (30–34). High expression of COX-2 and its product PGE2 (a 
mediator of inflammation and pain in OA) has been reported in joint tissues such as 
cartilage, synovium and infrapatellar fat pads in OA (5,6). Inhibitors of cyclooxygenases 
provide anti-inflammatory/analgesic effects (35) and are routinely used for symptomatic 
treatment in OA. Chondrocytes and synovium also produce 15-HETE (36,37), which has 
both pro- and anti-inflammatory properties in various tissues (38,39).
Our data also indicate that a PBL inflammatory transcriptome identifies a subset of SKOA 
patients at higher risk for radiographic disease progression, and may therefore serve as a 
prognostic biomarker. Similarly, two other studies have also reported elevated expression of 
IL-1β and TNFα in PBLs of OA patients (40,41). SKOA patients with the inflammatory 
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PBL transcriptome not only experienced more rapid progression of OA, but also exhibited 
more pain at presentation. Based on these findings, we speculate that PBLs are activated by 
exposure to inflammatory stimuli via repeated circulation through diseased synovium and 
subchondral bone of affected joints. This concept is consistent with the notion that OA is 
characterized by a state of chronic low-grade inflammation, wherein joint tissues are the site 
of production of cytokines, eicosanoids and activated complement components capable of 
stimulating PBLs that traverse these tissues (42). Hirohata et al (43) have shown increased 
expression of IL-6 and TNFα mRNAs by CD34+ hematopoietic precursors in bone marrow 
of both OA and RA patients relative to normal controls. Stannus et al (44) have reported that 
circulating levels of IL-6 and TNFα are associated with cartilage loss in OA. This finding 
raises the intriguing possibility that the activated PBLs observed in our studies originate 
from a pool of activated precursor cells in the bone marrow of SKOA joints.
Histologic analysis of synovial biopsies, as well as both contrast and non-contrast MRI 
imaging of knee joints, have shown that mild-to-moderate synovial inflammation is 
associated with increased likelihood of severe OA (3,7,45,46). Two independent groups 
have reported high levels of inflammatory cytokines in OA synovial fluid and plasma 
samples (42,47). High levels of inflammatory markers have been found systemically (blood 
cells) and locally (cartilage and synovium) in both murine and canine models of spontaneous 
OA (48,49). Additionally, synovial fluid IL-1β and IL-18 are associated with OA severity 
and progression (50). We (VBK) recently identified elevated levels of inflammatory 
synovial and plasma soluble macrophage markers (CD163 and CD14) associated with an 
inflammatory subset of knee OA patients with a worse prognosis (51).
OA is a disease of the joint that affects multiple tissues. Therefore, it is unlikely that a single 
biomarker could offer a broad description of this complex disease. A novel finding of our 
studies is that combinations of clinical and biological markers enhance the predictive 
capacity of individual biomarkers. Using a multivariate model, we show that the 
combination of demographic traits and clinical characteristics with PBL COX-2 gene 
expression, alone or in combination with IL-1β, predicts progressive radiographic JSN better 
than any individual biomarker. In the current study, associations of biomarkers with 
radiographic progression were revealed by different analytic approaches that included: 1) 
dichotomization of biomarkers at median level, and 2) threshold of radiographic progression 
by JSN.
Our studies do not show an independent effect of BMI on radiographic progression of 
SKOA. While a number publications have shown association of BMI with symptoms and 
incidence of OA, the literature is mixed regarding a clear association of BMI with OA 
progression (52–55). In our population with medial disease, only 17 patients had BMI >31, 
which may have attenuated the effects of obesity. Also, our study did not include assessment 
of alignment, which has been associated with progression linked to obesity. An interesting 
recent article by Wu et al (56) indicates that the relationship between BMI and progression 
may depend on genotype. In this study, consistent with the NYUHJD cohort, the rate of 
progression was not significantly higher in subjects with BMI greater than median (28.5 
kg/m2) compared to those below the median. However, there was an interaction between 
IL1RN gene variations and BMI, such that BMI association with progression was only 
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evident in subjects who carried the TGC haplotype (56). Recently, we (VBK) have reported 
that while BMI and WOMAC pain were diagnostically associated with OA, neither was 
prognostic (57).
In conclusion, our results indicate that increased plasma levels of the inflammatory 
biomarkers PGE2 and 15-HETE, as well as PBL transcriptome analyses, hold promise as 
early diagnostic and prognostic tests for OA. Furthermore, inflammatory biomarkers can be 
used to identify subgroups among subjects with clinical knee OA in whom the disease 
progresses at different rates. This can facilitate our understanding of OA pathogenesis and 
allow us to differentiate disease phenotypes within a heterogeneous knee OA population. A 
subgroup of OA with chronic, low-grade inflammation could be targeted for therapeutic 
interventions. Inflammatory biomarkers may be useful in the future to stratify the patients 
and develop personalized care for OA. Our longitudinal clinical study of OA indicates that 
biochemical biomarkers show significant promise with regard to prediction of radiographic 
JSN at 24 months. Finally, to advance success in treating and managing OA, efforts are 
needed to establish the temporal relationship between changes in inflammatory biomarkers 
or imaging and the progression of disease. Larger, longitudinally-followed and well-defined 
patient cohorts are necessary to validate our multivariate biomarker algorithm for prognostic 
use and to help screen appropriate participants for clinical trials of symptom- or disease-
modifying agents.
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Baseline plasma PGE2 is elevated in NYUHJD learning, NYUHJD progression and Pfizer 
cohorts. Plasma levels of PGE2 were determined using ACE EIA kit as described in 
Methods. The NYUHJD learning cohort (A) consists of symptomatic knee osteoarthritis 
(SKOA) cases (n=42) and non-OA controls (n=20); the NYUHJD progression cohort (B, D) 
consists of SKOA cases (n=178) and non-OA controls (n=21). A) Mean PGE2 levels in the 
learning cohort were 91.8±44.9 pg/ml (range: 35.4–249.1) in SKOA and 63.2±14.22 (41.2–
105.8) in controls. B) Mean PGE2 levels in the progression cohort were 159.0±83.8 (43.7–
690.2) in SKOA and 72.4±33.5 (13.53–152.1) in controls. The solid horizontal bar in each 
group represents the mean. Non-parametric, Mann-Whitney test was performed to calculate 
statistical significance using GraphPad Prism 4.0. The p values for cases versus controls are 
shown for each biomarker. C) Baseline plasma PGE2 in Pfizer validation cohort consists of 
SKOA cases (n=66) and non-OA controls (n=12). D) ROC curve of NYUHJD progression 
cohort baseline plasma PGE2 for distinguishing NYUHJD progression cohort SKOA cases 
from non-OA controls with age, gender and BMI. The curve line depicts AUC in the 10-fold 
cross-validation repeated 100 times.
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Baseline plasma 15-hydroxyeicosatetraenoic acid (15-HETE) is elevated in NYUHJD 
progression (A) and Pfizer validation cohorts (B). C) Baseline urinary type II collagen 
neoepitope (uTIINE) is elevated in Pfizer validation cohort [LC-MS/MS (Liquid 
Chromatography-Tandem Mass Spectrometry)]. The solid horizontal bar in each group 
represents the mean value. Non-parametric, Mann-Whitney test was performed to calculate 
statistical significance using GraphPad Prism 4.0. The p values for cases versus controls are 
shown for each biomarker.
Mean (±SD) 15-HETE (ng/ml) levels in NYUHJD progression SKOA cases were 0.44±0.48 
(0.0–2.3) and in controls and 0.22±0.26 (0.0–1.1), respectively. Mean (±SD) 15-HETE 
(ng/ml) levels in Pfizer SKOA cases were 1.3±0.45 (0.71–3.2), and in controls 0.72±0.16 
(0.49–0.94), respectively.
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Prostaglandin E synthase mRNA is elevated in SKOA patients. A) Hierarchical clustering of 
NYUHJD learning cohort SKOA cases and non-OA controls based on prostaglandin E 
synthase U133A probe sets. B) Receiver operating characteristic (ROC) curve of membrane 
PGE synthase (Affymetrix U133A array probe sets (207388_s_at, 200627_at, 210367_s_at, 
218083_at) for distinguishing NYUHJD Learning cohort SKOA cases from non-OA 
controls with and without age, gender and BMI. The curve line depicts the AUC in the 10-
fold cross validation repeated 100 times. The dotted line represents the ROC curve of null 
model AUC (0.5). C) ROC curve of plasma PGE2 levels from ex vivo blood PBL cultures 
distinguishing NYUHJD progression cohort SKOA cases from non-OA controls with and 
without age, gender and BMI. The curve line depicts AUC in the 10-fold cross validation 
repeated 100 times.
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